Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Peter Singleton who wrote (19852)	4/30/1998 7:34:00 PM
From: RXGOLF	Respond to of 32384

<<This is very encouraging for LGND's cancer trials ... given FDA's receptivity to this submission>> I agree with you Peter.In 1996, of the 53 new molecular entities(NME), 19 of them received a priority rating by the FDA.Drugs with a 1P rating had a much shorter median review time(6 months). The longest review time was approx. 100.3 months. The shortest review times were 1.4 and 2.4 months for two new protease inhibitors. Of all the talk of a speedier FDA, I find it of interest that in 1995 the ave. review time was 19 months, and in 1996 it went up to 20.5 months. Go figure!! RXGOLF